A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 79,249 shares of ONCY stock, worth $75,286. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,249
Previous 137,085 42.19%
Holding current value
$75,286
Previous $135,000 49.63%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.87 - $1.08 $50,317 - $62,462
-57,836 Reduced 42.19%
79,249 $68,000
Q2 2024

Aug 14, 2024

SELL
$0.99 - $1.24 $25,423 - $31,843
-25,680 Reduced 15.78%
137,085 $135,000
Q1 2024

May 15, 2024

BUY
$0.89 - $1.36 $43,503 - $66,476
48,880 Added 42.92%
162,765 $172,000
Q4 2023

Feb 14, 2024

BUY
$1.22 - $2.09 $138,939 - $238,019
113,885 New
113,885 $153,000
Q1 2023

May 15, 2023

BUY
$1.2 - $1.91 $60,704 - $96,621
50,587 Added 135.73%
87,858 $105,000
Q4 2022

Feb 14, 2023

BUY
$1.17 - $2.12 $43,607 - $79,014
37,271 New
37,271 $60,000
Q2 2022

Aug 15, 2022

SELL
$0.85 - $1.59 $9,893 - $18,506
-11,639 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.31 - $2.02 $109,641 - $169,065
-83,696 Reduced 87.79%
11,639 $18,000
Q4 2021

Feb 14, 2022

BUY
$1.39 - $2.3 $108,902 - $180,198
78,347 Added 461.19%
95,335 $132,000
Q3 2021

Nov 15, 2021

SELL
$1.93 - $2.77 $23,933 - $34,350
-12,401 Reduced 42.2%
16,988 $36,000
Q2 2021

Aug 16, 2021

SELL
$2.6 - $4.64 $51,971 - $92,748
-19,989 Reduced 40.48%
29,389 $81,000
Q1 2021

May 17, 2021

BUY
$2.32 - $4.11 $114,556 - $202,943
49,378 New
49,378 $188,000
Q4 2020

Feb 16, 2021

SELL
$1.71 - $4.03 $39,567 - $93,250
-23,139 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$1.58 - $2.15 $23,537 - $32,028
-14,897 Reduced 39.17%
23,139 $39,000
Q2 2020

Aug 14, 2020

BUY
$1.33 - $2.76 $50,587 - $104,979
38,036 New
38,036 $72,000
Q1 2020

May 15, 2020

SELL
$0.98 - $4.28 $31,815 - $138,950
-32,465 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.42 - $4.76 $6,530 - $74,013
15,549 Added 91.92%
32,465 $154,000
Q3 2019

Nov 14, 2019

BUY
$0.54 - $1.71 $9,134 - $28,926
16,916 New
16,916 $9,000
Q2 2019

Aug 14, 2019

SELL
$1.63 - $1.95 $48,117 - $57,564
-29,520 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$1.77 - $2.31 $52,250 - $68,191
29,520 New
29,520 $0

Others Institutions Holding ONCY

About ONCOLYTICS BIOTECH INC


  • Ticker ONCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 57,867,400
  • Market Cap $55M
  • Description
  • Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...
More about ONCY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.